Status:
UNKNOWN
Impact of Modifications to the Rendering of the Antibiogram on the Prescriptions of Meropenem in Pseudomonas Bacteremia
Lead Sponsor:
University Hospital, Strasbourg, France
Conditions:
Pseudomonas
Eligibility:
All Genders
18+ years
Brief Summary
Modification of the rendering of the antibiogram at the Strasbourg University Hospital in November 2019 with the appearance of the concept of "standard dose" or "high dose" sensitivity. This modifica...
Eligibility Criteria
Inclusion
- Major subject (≥18 years old)
- Subject with a positive blood culture result for Pseudomonas spp identified in the microbiology laboratory of Strasbourg University Hospital during the period from June 1, 2018 to November 30, 2022
- Subject not opposing the reuse of their data for the purposes of this research.
Exclusion
- Subject having expressed opposition to participating in the study,
- Pseudomonas spp strain resistant to all first-line beta-lactams (Piperacillin-Tazobactam, Ceftazidime, Céfepime and Aztreonam).
- Pseudomonas spp strain resistant to Meropenem.
- Lack of information on the antibiotic treatment undertaken.
Key Trial Info
Start Date :
March 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 13 2024
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT06113107
Start Date
March 1 2023
End Date
March 13 2024
Last Update
November 2 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Service des Maladies Infectieuses et Tropicales - CHU de Strasbourg - France
Strasbourg, France, 67091